NEONATAL RESPIRATORY DISTRESS SYNDROME 
World’s first rapid LUNG MATURITY SCREENING test 

  • First diagnostic test available on our patented Clinical AI platform and device 
  • Clinically proven to predict RDS1,2  hours before symptoms develop
  • Current diagnostics are too slow to be clinically effective, so treatment is often
    delayed, expensive and sub-optimal
  • By enabling early and preventative treatment, our point-of-care screening test will help give premature babies a fighting chance
  • Product phase: Final validation and product launch preparation*
CLINICAL TRIAL: FAST ASSESSMENT OF LUNG MATURITY AT BIRTH

NEONATAL CHRONIC LUNG DISEASE 
FoR THE FIRST TIME CLD CAN BE PREDICTed hours after birtH   

  • Second screening test developed for our patented Clinical AI Platform and device 
  • Developed by analysing diagnostic and clinical data with AI
  • Clinically proven to predict Chronic Lung Disease in minutes3,4  
  • Will enable targeted treatment of one of the most poorly understood and complex diseases in premature babies
  • Product phase: Final design and development (clinical validation)*
AI Predicts Newborn Chronic Lung Disease in Breakthrough Clinical Study
References: Clinical publications
  1. Rapid test for lung maturity, based on spectroscopy of gastric aspirate, predicted respiratory distress syndrome with high sensitivity – Acta Paediatr. 2016:  doi: 10.1111/apa.13683. VIEW CLINICAL PUBLICATION
  2. Predicting respiratory distress syndrome at birth using a fast test based on spectroscopy of gastric aspirates: 2. Clinical part – Acta Paediatr. 2019:  doi: 10.1111/apa.14831. VIEW CLINICAL PUBLICATION
  3. Bronchopulmonary dysplasia predicted at birth by artificial intelligence – Acta Paediatr. 2020:  doi: 10.1111/apa.15438. VIEW CLINICAL PUBLICATION
  4. Early prediction of bronchopulmonary dysplasia is possible and important – Acta Paediatr. 2020: doi: 10.1111/apa. 15508. VIEW CLINICAL PUBLICATION

*For investigational use only